Will the era of domestic biosimilar successes open?

Published: 2015-03-17 16:27:00
Updated: 2015-03-17 13:49:08

As the first biosimilar, the Sandoz’s ‘Zarxio (generic name: filgrastim)’, has recently acquired sale approvals in the U.S., biosimilars developed by domestic companies have attracted attention of the industry.

As a domestic biosimilar entered the U.S. market, the largest pharmaceutical market, ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.